Adjuvant chemotherapy improves patient survival rates after resection for pancreatic adenocarcinoma, but the optimal duration and time to initiate chemotherapy is unknown.
INTRODUCTION
Pancreatic ductal adenocarcinoma is a highly challenging disease with a 5-year survival rate of less than 5%. 1 Although most patients present with advanced disease, the best outcomes are seen in patients who undergo resection of their primary tumor at specialized centers. 2, 3 Surgery alone achieves a 5-year survival rate of approximately 10%, 3 whereas a number of randomized studies have shown improved survival rates with the ad-dition of adjuvant chemotherapy after potentially curative resection. 4-10 Thus, 5-year survival figures in the European Study Group for Pancreatic Cancer (ESPAC) -1 study were 8% for surgery alone versus 21% when adding fluorouracil (FU) and folinic acid after surgery. 5, 6 The ESPAC-3 trial, 8 the largest adjuvant study in this setting, was a prospective, randomized phase III chemotherapy study of FU and folinic acid (n ϭ 551) versus gemcitabine (n ϭ 537); a third, observationalone arm was closed after the definitive results of The results of ESPAC-3 showed no significant differences between the two treatment arms with a median survival of 23.0 months in the FU arm and 23.6 months in the gemcitabine arm, and with no differences in global quality of life scores although gemcitabine had an improved safety profile. 8 In practice, adjuvant chemotherapy is initiated within a few weeks from the date of surgery. Although survival rates have been shown not to be affected by postoperative complications, 8, 11 it is unknown whether the use of adjuvant chemotherapy should still start as soon as possible after surgery or if it may be safely delayed to allow further postoperative recovery without compromising long-term survival. Also, it is not known whether the full six cycles of adjuvant chemotherapy need to be administered or whether fewer cycles may have a similar survival benefit.
A number of preclinical observations in cancer would support the concept of early initiation of adjuvant chemotherapy. Metastasis is an early event in the development of pancreatic cancer 12 and removal of a primary tumor may accelerate growth of micrometastases, 13 potentially causing the release of growth factors that may stimulate micrometastases at distant sites. 14 In addition, delay in starting treatment may result in the establishment of drug-resistant micrometastases 15 and an increase in angiogenesis in the vascular bed surrounding metastases. 16 Within the ESPAC-3 protocol, patients were to start allocated adjuvant chemotherapy within 6 weeks of surgery, although patients with delayed postoperative recovery were allowed to wait up to 12 weeks. 8 Previous multivariable analysis had identified tumor grade, tumor size, nodal status, performance status, and smoking status as significant independent prognostic factors of overall survival. 8 We performed a further analysis to investigate the effect that the time between surgery and the start of chemotherapy, as well as the completion of planned chemotherapy, had on the long-term survival of patients in this trial.
PATIENTS AND METHODS

Patient Selection
Patients with pancreatic ductal adenocarcinoma were selected from the ESPAC-3 (version 2) trial, an open label, international, randomized phase III study to investigate whether gemcitabine was superior to FU and folinic acid (Trial Registration details: Old CTA Ref., 12155/0001/001; New CTA Ref., 12155/0207/001; Former DDX Ref., MF8000/9956: ISRCTN, 37494643) . Patients initially randomly assigned to the observation arm are not included in this analysis. The study was performed after approval from relevant research ethics committees (MREC: 99/8/74).
Statistical Analysis
Analysis was carried out on the long-tem overall survival measured from the date of resection to the date of death from any cause. Patients who did not die during the course of the trial were censored at the date last seen alive. Survival estimates were calculated using the method of Kaplan and Meier 17 and were compared across biologic groups using log-rank tests. 18 Median and 95% CIs of 24-month and 60-month survival estimates were calculated. Multivariable Cox regression 19 techniques were used to adjust the overall treatment effect by all important prognostic variables on a complete case basis. Covariates were included in the multivariable model using forward stepwise selection based on the Akaike Information Criterion if they had an unadjusted log-rank significance of P Ͻ .25. 20 Initial exploratory analyses showed that the time to the start of treatment had a different effect depending on whether or not a patient completed therapy, which was therefore included as a nested effect. Here, the model allows separate terms to describe the effect of time to treatment, depending on whether or not a patient completed the planned six cycles of therapy.
Following analysis of the full data set, a subgroup sensitivity analysis was carried out using the landmark method 21 by removing from the data any patient who died within 8 months after surgery. This analysis was performed to remove any potential bias as a result of treatment-related deaths. As the choice of an 8-month landmark point was somewhat arbitrary, further sensitivity analyses using landmarks of 9 to 12 months were also considered. Time to treatment was primarily modeled as a continuous covariate, although sensitivity analyses also include time to treatment as a variable dichotomized at the median time from surgery until treatment. The median was 8.2 weeks (interquartile range [IQR], 6.7 to 9.7 weeks) rounded down to 8 weeks. The assumption of proportional hazards was satisfied via assessment of Schoenfeld residuals. 22 Analyses were carried out using the statistical package R (version 2.13.1) on an intention-to-treat basis, retaining patients in their randomized treatment groups and including protocol violators and ineligible patients. A twosided significance level of P Ͻ .05 was used throughout.
RESULTS
There were 985 patients in the analysis (Fig 1) . Patients' clinical, surgical, and pathologic details are listed in Table 1 ; 486 patients (49%) were randomly assigned to the gemcitabine arm and 499 patients (51%) to the FU and folinic acid arm. Previous analyses indicating no significant overall survival difference between the two therapies was confirmed in this subset. 8 There were 674 patients (68%) who completed all six cycles of intended therapy, 294 patients (30%) received one to five cycles of therapy, and 17 patients (2%) had incomplete data regarding the number of cycles they received. There were similar proportions of patients receiving one to five cycles in each of the chemotherapy arms (FU, 32%; gemcitabine, 28%, respectively).
Overall Survival
The overall median follow-up period was 58.7 months (IQR, 49.1 to 65.3 months), 59.1 months (IQR, 50.0 to 68.9 months) for patients who completed all cycles of therapy and 56.0 months (IQR, 47.4 to 63.1 months) for those who did not. Seven hundred sixty-seven patients (78%) died; of the patients who died, 509 (75%) of 674 patients completed all cycles and 245 (84%) of 294 patients did not.
The overall median survival was 23.7 months (95% CI, 22.0 to 25.4). The effect on overall survival of the time between surgery and the start of treatment for patients who received all six cycles of planned therapy and those who received fewer than six cycles (including and excluding patients who died within 8 months of surgery) is shown in Figures 2 and 3 respectively. Statistical analyses of overall survival by clinical characteristics for the full patient set are listed in Appendix . Median survival was 28.0 months (95% CI, 26.1 to 30.9 months) for patients who completed all cycles of therapy versus 14.6 months (95% CI, 12.5 to 16.9 months) for those who did not complete therapy (HR, 0.516; 95% CI, 0.443 to 0.601; LR(1DF) 2 ϭ 74.627; P Ͻ .001; Appendix Fig A2) . Overall survival in six groups by the number of cycles received is shown in Appendix Figure A3 . Considering only the cohort of patients that had fewer than six cycles of therapy, chemotherapy start time was an important survival factor, in favor of late start for treatment (HR, 0.919; 95% CI, 0.868 to 0.973; (1DF) 2 ϭ 8.35; P ϭ .004). There were no significant differences in the reasons for discontinuing treatment between the early and late start to chemotherapy groups ( Table 2) .
Smoking status, baseline performance status, tumor grade of differentiation, lymph node involvement, local invasion, tumor stage, and resection margins were all considered categoric variables; age and the proportion of therapy received were considered continuous variables. The assumption of proportional hazards was satisfied. 22 There was no evidence that there was a country effect (data not shown). The time between surgery and the start of therapy was not included as a main effect in the multivariable model (P ϭ .319) but was included as an effect nested within the completion of therapy variable.
A model based on 949 patients (741 deaths) identified lymph node involvement, completion of therapy, resection margins, and tumor differentiation as important independent survival factors. Postoperative CA19-9 was not considered for inclusion in the Cox model because of the large number of missing values. The time to the start of therapy was only identified as an important factor for the subgroup of patients who did not complete therapy with reduced survival observed in patients starting chemotherapy early (P ϭ .004).
Recurrence-Free Survival
The median recurrence-free survival rate for all patients was 14.29 months (95% CI, 13.47 to 15.14 months) and was not influ-enced by time to starting chemotherapy (Appendix Table A2 ). Median recurrence-free survival for patients commencing within 8 weeks of surgery was 13.83 months (95% CI, 12.41 to 15.46 months) compared with 14.82 months (95% CI, 13.62 to 16.34 months) for those starting later than 8 weeks (Appendix Figure A4 ). The unadjusted effect of time between surgery and the start of therapy as a continuous variable was not significant (HR, 0.988; 95% CI, 0.96 to 1.016; LR(1DF) 2 ϭ 0.70; P ϭ .40; Appendix Table A3 ). Median recurrence-free survival was 16.56 months (95% CI, 15.14 to 17.94 months) for patients who completed all cycles of therapy versus 8.90 months (95%CI, 7.79 to 10.35 months) for those who did not (HR, 0.564; 95% CI, 0.49 to 0.66; LR(1DF) 2 ϭ 58.541; P Ͻ .001). When considering only the cohort of patients who had fewer than six cycles of therapy, chemotherapy start time was an important survival factor, in favor of late start for treatment (HR, 0.937; 95% CI, 0.885 to 0.992; (1DF) 2 ϭ 5.08; P ϭ .012). Factors with a log-rank significance of P Ͻ .25 were considered for inclusion in the multivariable Cox model.
A model based on 949 patients (797 deaths) identified lymph node involvement, completion of therapy, resection margins, and tumor differentiation as important independent survival factors. The assumption of proportional hazards was satisfied. 22 The time to the start of therapy was only identified as an important factor for the subgroup of patients who did not complete therapy with reduced recurrence-free survival observed in patients starting chemotherapy early (P ϭ .012; Appendix Table A3 ).
Subgroup Analysis, Excluding Early Deaths
A landmark analysis was carried out, excluding all patients who died within 8 months of surgery (n ϭ 889). Of these, 449 patients (50%) were randomly assigned to gemcitabine and 440 patients (50%) to FU plus folinic acid; 408 patients (46%) received adjuvant chemotherapy within 8 weeks after surgery and 481 patients (54%) received adjuvant chemotherapy later than 8 weeks (Table 1) . Overall median follow-up time was 59.1 months (IQR, 50.0 to 65.8 months); this was 57.8 months (IQR, 49.5 to 71.2 months) for the early-treatment group and 59.4 months (IQR, 50.0 to 65.0 months) for the late-treatment group. There were 685 patient deaths (77%), 316 (79%) in the early-treatment group and 369 (77%) in the latetreatment group. Statistical analyses of overall survival by clinical characteristics are listed in Appendix Table A4 .
The median survival was 25.9 months (95% CI, 24.1 to 27.7 months). Survival was 25.5 months (95% CI, 22.9 to 28.6 months) for the early-treatment group and 25.9 months (95% CI, 23.9 to 28.9 months) for the late-treatment group, and the unadjusted analysis of the continuous variable was not significant (HR, 0.985; 95% CI, 0.95 to 1.02; LR(1DF) 2 ϭ 0.831; P ϭ .362). Median survival was 28.35 months (95% CI, 26.1 to 31.0 months) for patients who completed all cycles of therapy versus 19.3 months (95% CI, 17.3 to 21.8 months) for those who did not complete therapy (HR, 0.667; 95% CI, 0.56 to 0.79; LR(1DF) 2 ϭ 22.06; P Ͻ .001). In patients who had fewer than six cycles of therapy, the median survival was 16.5 months (95% CI, 14.6 to 20.3 months) for the early-treatment group and 21.9 months (95% CI, 18.5 to 26.8 months) for the late-treatment group ( LR(1DF) 2 ϭ 4.33; P ϭ .038).
A model based on 872 patients (674 deaths) identified lymph node involvement, the completion of therapy, tumor grade differentiation, and resection margins as independent survival factors. The assumption of proportional hazards was satisfied. 22 There was no significant difference in overall survival with respect to the time between surgery and randomization (data not shown). A further subgroup analysis was carried out to investigate only the group of patients who did not complete therapy. Again, earlier therapy was shown to be detrimental to long-term survival ( adj HR, 0.934; P ϭ .046; analysis not included).
Further analyses of overall survival were carried out using 9 to 12 months as additional landmark points. These show that there are no major changes in the interpretation of the multivariable analyses owing to the choice of landmark used or for which time to the start of treatment was considered as a dichotomized variable (Appendix Table A5 ).
Inclusion of Postoperative CA19-9 in Analysis
CA19-9 levels were missing in 247 patients as this test was not routinely available at all institutions. Multivariable Cox models were fitted both with and without this variable and confirmed that CA19-9 was an independently significant variable (data not shown).
Subgroup Analysis of the Early-Deaths Group
There were 96 patients who died within 8 months after surgery (early death) of whom 58 (60%) had disease progression before death compared with 747 (76%) of 985 patients in the full data set. The 30-day chemotherapy mortality rate was eight (0.8%) of 985 patients, suggesting that early deaths were not chemotherapy-related. The cause of death for patients with an early death was not significantly different to other patients (Appendix Table A4 ). The overall survival of the early-death group of patients was not affected by when patients started therapy (Appendix Fig A5) . The effects of including the earlydeath group of patients in the full analysis produced similar conclusions at the 5% level of significance.
DISCUSSION
Surgical resection followed by chemotherapy with FU and folinic acid, gemcitabine, or S-1 (oral fluoropyrimidine-tegafur/gimeracil/oteracil combination capsule) offers the best chance of long-term cure for patients with pancreatic cancer. [4] [5] [6] [7] [8] [9] [10] In keeping with other adjuvant strategies for most solid tumors, treatment is usually planned to start as soon as possible postoperatively. Pancreas cancer surgery is however associated with a high morbidity so patients do not all recover at the same rate. Before surgery, many patients may already be nutritionally compromised from main pancreatic duct and main bile-duct obstruction and may also be recovering from obstruction jaundice and related sepsis. It is not known whether delaying treatment to allow for a full postoperative recovery before starting adjuvant chemotherapy affects long-term survival.
Computational modeling of pancreatic cancer therapy has predicted that aggressive full-dose systemic therapy was needed to suppress tumor proliferation and that earlier initiation had a better survival than a later start. 23 This model was developed on a group of 101 pancreatic patients who had consented for autopsy and then validated on another set of 127 patients who underwent adjuvant radiation therapy and chemotherapy after their resections. 23 Nevertheless, such a study based on retrospective cohorts has underlying biases in patient selection and biases in the choice of adjuvant treatments that will influence survival. To better test these hypotheses, the intrinsic biases can be minimized by appropriate statistical modeling and sensitivity analyses of data from prospective randomized controlled trials.
This study was an intention-to-treat analysis of 985 eligible patients randomly assigned to one of two equally effective chemotherapy arms with exclusion of surgery-alone patients. The best recurrence-free and overall survival was observed in patients who had received all of the planned six cycles of treatment compared with those who had received between one and five cycles only. For patients who had completed all six cycles of chemotherapy, there was no difference in overall survival whether treatment was started early, namely within 8 weeks of surgery, or later, at 8 to 12 weeks after surgery. In patients who completed fewer than six cycles of chemotherapy, there was reduced recurrence-free and overall survival when starting treatment early, which may be related to insufficient time-dependent recovery from postoperative immune suppression. [24] [25] [26] These findings held true after adjusting for independent survival factors, including lymph node involvement, resection margin status, and tumor differentiation, with completion of therapy remaining an independent predictor of survival. In the multivariable analysis, the time to the start of therapy was only identified as an important factor for the subgroup of patients who did not complete all six cycles of chemotherapy, with reduced recurrence-free and overall survival when starting treatment early. CA19-9 levels, in keeping with previous studies, was again shown to be an independent prognostic variable, 27-31 but was not included in the final model in order to focus on the primary questions and extend the number of sensitivity analyses.
A further potential bias could arise by including patients who experience early death as a result of disease progression and, hence, might not complete all six cycles of chemotherapy. Thus, a further sensitivity analysis was undertaken after excluding patients who had died within 8 months after surgery. Analysis of this subgroup of the remaining 889 patients again showed the improved overall and recurrence-free survival effects of fully completing the planned chemotherapy was maintained. The requirement for completing all six cycles of adjuvant chemotherapy after pancreatic cancer resection to obtain the best survival may have contributed to the lack of randomized phase III data to support the use of adjuvant chemoradiotherapy as the total dose of adjuvant systemic chemotherapy is reduced in this context, 5,6,32-34 although there may be other reasons. 35, 36 Completion of all six cycles of adjuvant chemotherapy was an independent favorable prognostic variable. There was no survival disadvantage from delaying the start of treatment for up to 12 weeks after surgery. Conversely, there was no survival advantage for starting early treatment, within 8 weeks of surgery. In routine clinical practice, though it is not possible to know in the immediate postoperative setting whether a patient will go on to complete the full course of treatment, ensuring adequate postoperative recovery is likely to maximize this chance. Patients who feel stronger after a slightly longer period of postoperative convalescence may be more likely to stay the full course of adjuvant chemotherapy. Thus, the 14. Ziprin P, Ridgway PF, Pfistermü ller KL, et al: ICAM-1 mediated tumor-mesothelial cell adhesion is modulated by IL-6 and TNF-alpha: A potential mechanism by which surgical trauma increases peritoneal metastases. Cell Commun Adhes 10: [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] [151] [152] [153] [154] 2003 15. DeVita VT Jr: The James Ewing lecture: The relationship between tumor mass and resistance to chemotherapy-Implications for surgical adjuvant treatment of cancer. Cancer 51: [1209] [1210] [1211] [1212] [1213] [1214] [1215] [1216] [1217] [1218] [1219] [1220] 1983 16. Nguyen DX, Bos PD, Massagué J: Metastasis: From dissemination to organ-specific colonization. Nat Rev Cancer 9: [274] [275] [276] [277] [278] [279] [280] [281] [282] [283] [284] 2009 17. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 1958 18. 
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